Ironwood Pharmaceuticals (IRWD) Liabilities and Shareholders Equity (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $434.6 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $434.6 million, up 32.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 7.33% YoY), and the FY2025 annual result was $396.9 million, up 13.11% from the prior year.
• Liabilities and Shareholders Equity came in at $434.6 million for Q1 2026 at Ironwood Pharmaceuticals, up from $396.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.2 billion in Q1 2023 to a low of $327.2 million in Q1 2025.
• The 5-year median for Liabilities and Shareholders Equity is $438.8 million (2024), against an average of $613.3 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 80.76% in 2022 and plunged 62.02% in 2024, its largest moves.
• Ironwood Pharmaceuticals' Liabilities and Shareholders Equity stood at $1.1 billion in 2022, then tumbled by 57.2% to $471.1 million in 2023, then declined by 25.51% to $350.9 million in 2024, then grew by 13.11% to $396.9 million in 2025, then rose by 9.49% to $434.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $434.6 million (Q1 2026), $396.9 million (Q4 2025), and $396.1 million (Q3 2025), per Business Quant data.